New PET Imaging Scans for Advanced Solid Tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have one of these cancer types: pancreatic, non-small-cell lung, hormone-receptor positive breast, triple-negative breast, colorectal, or soft-tissue sarcoma
- Your cancer is advanced (cannot be surgically removed or has spread) and you have at least one measurable tumor on CT or MRI
- Your kidney, liver, and blood cell counts are within acceptable ranges
- You have a tumor tissue sample (biopsy) available from your medical records
- You have not had surgery, radiation, or major cancer treatment changes in the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
This study tests a new type of PET scan (a detailed imaging test) called [68Ga]Ga-FAPI that may help doctors see cancer better and faster than standard scans. You'll receive this experimental scan to see if it improves cancer detection before surgery.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This Phase 1 trial tests a new imaging agent (a radioactive tracer) that helps doctors see pancreatic cancer that has spread or cannot be removed by surgery. The scan uses positron emission tomography (PET), a type of imaging that detects cancer cells.
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.